ライフサイエンスコーパス: ezetimibe

1 -10.8]; p<0.0001 for all doses vs placebo or ezetimibe).

2 terol (7% [4-11] vs placebo and 8% [4-13] vs ezetimibe).

3 alirocumab, 1174 taking placebo, 618 taking ezetimibe).

4 olesterol, particularly after treatment with ezetimibe.

5 its response to a cholesterol-lowering drug, ezetimibe.

6 h-fat/high-cholesterol diet, with or without ezetimibe.

7 st 8 weeks of statin therapy with or without ezetimibe.

8 xamined statins, and 2 examined statins plus ezetimibe.

9 ated with high-dose statins, with or without ezetimibe.

10 stable diet and statin dose, with or without ezetimibe.

11 of different doses of AMG145 and AMG145 plus ezetimibe.

12 mibe, and 1 patient (3.1%) receiving placebo/ezetimibe.

13 sporter (Niemann-Pick C1-like 1) is the CAI, ezetimibe.

14 without the cholesterol absorption inhibitor ezetimibe.

15 MT with niacin, and progression of CIMT with ezetimibe.

16 with a statin and that niacin is superior to ezetimibe.

17 -reactive protein, than low-dose statin plus ezetimibe.

18 sitive to a cholesterol absorption inhibitor ezetimibe.

19 for consideration in patients intolerant to ezetimibe.

20 tatin monotherapy and 1.7% used statins plus ezetimibe.

21 62-70) versus placebo and 40% (36-45) versus ezetimibe.

22 51-69) versus placebo and 39% (32-47) versus ezetimibe.

23 g drug, the cholesterol absorption inhibitor ezetimibe.

24 rol at 12 weeks for evolocumab, placebo, and ezetimibe.

25 Ezetimibe (1), a strong beta-lactamic cholesterol absorp

26 reatment with combined simvastatin 40 mg and ezetimibe 10 mg daily or placebo.

27 LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of ma

28 randomly assigned to simvastatin 20 mg plus ezetimibe 10 mg daily versus matching placebo.

29 biopsy-proven NASH were randomized to either ezetimibe 10 mg orally daily or placebo for 24 weeks.

30 neous placebo Q2W or QM both with daily oral ezetimibe 10 mg.

31 or 420 mg or placebo every 4 weeks; or oral ezetimibe 10 mg/day.

32 isease with simvastatin 40 mg/d, simvastatin/ezetimibe 10/10 mg/d, or placebo tablets for 28 days (n=

33 utaneous evolocumab (420 mg monthly) or oral ezetimibe (10 mg daily).

34 ) with placebo (every 2 weeks or monthly) or ezetimibe (10 mg or placebo daily; atorvastatin patients

35 ase niacin (target dose, 2000 mg per day) or ezetimibe (10 mg per day).

36 The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared w

37 andomly assigned to simvastatin (20 mg) plus ezetimibe (10 mg) daily or matching placebo.

38 ansplant patients were randomized to receive ezetimibe (10 mg) or matching placebo for 6 months in ad

39 e statin treatment were randomly assigned to ezetimibe (10 mg/day) or extended-release niacin (target

40 lacebo every 4 weeks 4.5% [-0.7 to 9.8]; and ezetimibe -14.7% [-18.6 to -10.8]; p<0.0001 for all dose

41 etimibe+phytosterol placebo, and (3) 10 mg/d ezetimibe+2.5 g phytosterols for 3 weeks each.

42 5% cholic acid, and 15% fat) without or with ezetimibe (7 mg/kg/d) for 6 wk.

43 ver 7 years were $453 per patient lower with ezetimibe (95% confidence interval, -$38 to -$869; P=0.0

44 Intestinal NPC1L1 appears to be a target of ezetimibe, a cholesterol absorption inhibitor that effec

45 ackground or when the mice were treated with Ezetimibe, a cholesterol-lowering drug that blocks intes

46 vascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal chol

47 NPC1L1 is the molecular target of ezetimibe, a potent cholesterol absorption inhibitor tha

48 niacin ([ERN], 1,500 to 2,000 mg/day), with ezetimibe added as needed, in both groups, to maintain a

49 ; HR, 0.52; 95% CI, 0.31-0.86; P=0.011) with ezetimibe added to simvastatin therapy.

50 rging evidence of cardiovascular benefit for ezetimibe, alirocumab, and evolocumab positions these dr

51 ontrol (2161 mg/d; 95% CI, 1112 to 3209) and ezetimibe alone (1054 mg/d; 95% CI, 546 to 1561; both P<

52 o control (505 mg/d; 95% CI, 386 to 625) and ezetimibe alone (794 mg/d; 95% CI, 615 to 973).

53 mibe and phytosterols is more effective than ezetimibe alone in altering cholesterol metabolism.

54 sterol values during treatment with control, ezetimibe alone, and ezetimibe+phytosterols averaged 129

55 tatin combined with bile acid sequestrant or ezetimibe among high-risk patients intolerant of or unre

56 Arabidopsis seedlings treated with ezetimibe, an inhibitor of M1 protein-protein interactio

57 The addition of ezetimibe, an intestinal cholesterol absorption inhibito

58 atine kinase (N = 218, with 73 randomized to ezetimibe and 145 to evolocumab; entry mean LDL-C level,

59 ts were assigned to receive simvastatin plus ezetimibe and 4620 to placebo.

60 mean age was 10.9 years; 8 patients were on ezetimibe and 7 on apheresis.

61 The controversial Simvastatin-Ezetimibe and Aortic Stenosis (SEAS) endpoint trial did

62 ommonly prescribed antihyperlipidemic drugs, ezetimibe and atorvastatin.

63 There was a significant difference between ezetimibe and niacin treatment groups on mean changes in

64 Declining ezetimibe and niacin use but not fibrate therapy among M

65 arly on decision making regarding the use of ezetimibe and PCSK9 inhibitors in patients with clinical

66 Both ezetimibe and phytosterols inhibit cholesterol absorptio

67 ested the hypothesis that the combination of ezetimibe and phytosterols is more effective than ezetim

68 red by MRI-PDFF (mean difference between the ezetimibe and placebo arms -1.3%, P = 0.4).

69 tography-derived liver stiffness between the ezetimibe and placebo arms.

70 tment, and consensus pathways suggest use of ezetimibe and proprotein convertase subtilisin/kexin typ

71 weekly; oral placebo and SC placebo monthly; ezetimibe and SC placebo biweekly; ezetimibe and SC plac

72 monthly; ezetimibe and SC placebo biweekly; ezetimibe and SC placebo monthly; oral placebo and evolo

73 7,717 post-ACS patients randomized either to ezetimibe and simvastatin or to placebo and simvastatin

74 ormin, thiazolidinediones, fibrates, niacin, ezetimibe and statins in improving the steatosis compone

75 encoding the respective molecular targets of ezetimibe and statins, have previously been used as prox

76 nt LDL-C reductions compared with placebo or ezetimibe and was well tolerated in patients with hyperc

77 ontinued all lipid-lowering treatment except ezetimibe and/or apheresis.

78 on with rosuvastatin 20 mg alone or added to ezetimibe and/or apheresis.

79 A diet supplemented with Zetia (ezetimibe) and lovastatin increased and decreased nuclea

80 ) (31% [25-37] vs placebo and 26% [16-35] vs ezetimibe), and an increase in HDL cholesterol (7% [4-11

81 r 150 mg every 2 weeks) and control (placebo/ezetimibe), and analyzed by background statin type/dose.

82 l (38% [32-44] vs placebo and 24% [16-31] vs ezetimibe), and lipoprotein(a) (31% [25-37] vs placebo a

83 % allocated to alirocumab, 6.5% allocated to ezetimibe, and 0% allocated to placebo).

84 , 6 patients (20.0%) receiving 420-mg AMG145/ezetimibe, and 1 patient (3.1%) receiving placebo/ezetim

85 statin monotherapy, 18.7% with statins plus ezetimibe, and 14% with add-on PCSK9 inhibitor.

86 Conventional therapy is with statins, ezetimibe, and apheresis.

87 es, such as pretreatment with beta-blockers, ezetimibe, and proprotein convertase subtilisin kexin ty

88 mens that employ a statin with added niacin, ezetimibe, and/or bile acid sequestrants, and to underst

89 eported in 36%, 40%, and 39% of evolocumab-, ezetimibe-, and placebo-treated patients, respectively.

90 therosclerotic lesions, whereas results with ezetimibe are uncertain.

91 ment MRI-PDFF was significantly lower in the ezetimibe arm (15%-11.6%, P < 0.016) but not in the plac

92 Ezetimibe assignment was open label.

93 revent 4.3 million MACE compared with adding ezetimibe at $414,000 per QALY (80% UI, $277,000-$1,539,

94 nic diet and concomitantly administered with ezetimibe at 0, 0.8, 4, or 8 mg/kg/day for 8 or 12 weeks

95 r atorvastatin at a dose of 80 mg daily plus ezetimibe at a dose of 10 mg daily, for a run-in period

96 isation was stratified by concomitant use of ezetimibe at baseline.

97 completely offset the cost of the drug once ezetimibe becomes generic, and may lead to cost savings

98 t, bile acid sequestrants, ileal bypass, and ezetimibe) (between-group difference, P = .72).

99 is regulated by cholesterol binding and that ezetimibe blocks NPC1L1-GFP function by inhibiting its e

100 d based upon the structure and properties of ezetimibe, but none remain in development.

101 onventional statin treatment with or without ezetimibe, but that it has the potential to induce liver

102 arotid atherosclerosis is indeterminate, but ezetimibe can be reasonably added to statin therapy as a

103 low-fat/no-cholesterol diet, with or without ezetimibe (cholesterol-lowering drug), and high-fat/high

104 Type of LDL-receptor mutation, use of ezetimibe, coexistent diabetes, and ASCVD status can bea

105 ar for high-dose simvastatin and simvastatin/ezetimibe combination therapy, but the magnitude of the

106 omatic AS patients randomized to simvastatin/ezetimibe combination versus placebo in the SEAS (Simvas

107 mptomatic patients randomized to simvastatin/ezetimibe combination versus placebo in the Simvastatin

108 Clinical outcome data with ezetimibe combined with simvastatin have recently become

109 wer cardiovascular hospitalization rate with ezetimibe compared with placebo (risk ratio, 0.95; 95% c

110 cremental LDL-C lowering attributable to the ezetimibe component reduces cardiovascular events beyond

111 week, randomized, double-blind, placebo- and ezetimibe-controlled study conducted between January and

112 week, randomized, double-blind, placebo- and ezetimibe-controlled, dose-ranging study conducted betwe

113 armacology of the cholesterol-lowering agent ezetimibe corroborates its potential carcinogenicity.

114 the potent cholesterol absorption inhibitor ezetimibe could prevent gallstones and promote gallstone

115 Mid-intensity statin plus ezetimibe decreased LDL cholesterol level 5% to 15% and

116 Ezetimibe did not significantly reduce liver fat in NASH

117 monitor NPC1L1-GFP endocytosis and show that ezetimibe does not alter the rate of NPC1L1-GFP endocyto

118 ere was a significant increase in the use of ezetimibe, drug combinations with statins, and maximal L

119 stine tissues from 24-week-old offspring fed ezetimibe during lactation, compared with controls.

120 iemann-Pick C1-Like 1 (NPC1L1) receptor with ezetimibe, either alone or in combination with a 3-hydro

121 tive to the cholesterol absorption inhibitor ezetimibe (EZE).

122 erol absorption inhibitors (CAIs), including ezetimibe (EZE).

123 us the non-statin cholesterol-lowering drug, Ezetimibe (EZT) on severity of diabetic nephropathy.

124 nduces regression of CIMT and is superior to ezetimibe for patients taking statins.

125 ts was lower in the niacin group than in the ezetimibe group (1% vs. 5%, P = 0.04 by the chi-square t

126 -15%; 95% CI, -23% to -7.0%) for the placebo/ezetimibe group (P < .001).

127 (-63%; 95% CI, -71% to -55%) for the 420-mg/ezetimibe group compared with -14 mg/dL (-15%; 95% CI, -

128 ), and the mean LDL cholesterol level in the ezetimibe group decreased by 19.2%, to 66 mg per decilit

129 oint at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastat

130 iter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter

131 o groups, and 26 (58%) of 45 patients in the ezetimibe group; no deaths or serious treatment-related

132 fewer patients allocated to simvastatin plus ezetimibe had a non-fatal myocardial infarction or died

133 Specific analysis confirmed ezetimibe had no significant effect on cyclosporin level

134 Similarly, allocation to simvastatin plus ezetimibe had no significant effect on the prespecified

135 At 6 months, ezetimibe had reduced total cholesterol by 18% (5.4+/-1.

136 Ezetimibe improved cardiovascular outcomes when added to

137 Ezetimibe improves cardiovascular (CV) outcomes in patie

138 ients most likely to benefit from the use of ezetimibe in addition to statin therapy after acute coro

139 Treatment with ezetimibe in an amount sufficient to block intestinal ch

140 ic stenosis participating in the Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study.

141 itial asymptomatic AS in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study.

142 nation versus placebo in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study.

143 years of follow-up in the SEAS (Simvastatin Ezetimibe in Aortic Stenosis) study.

144 versus placebo in the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study.

145 e used data from the SEAS trial (Simvastatin Ezetimibe in Aortic Stenosis) to assess what blood press

146 Lowering cholesterol plasma levels with ezetimibe in apoE(-/-) mice reversed iNKT function and M

147 l assessing the efficacy and tolerability of ezetimibe in cardiac transplant recipients receiving cyc

148 te cost-effectiveness of PCSK9 inhibitors or ezetimibe in heterozygous FH or ASCVD.

149 f subcutaneous evolocumab compared with oral ezetimibe in hypercholesterolemic patients who are unabl

150 and monthly evolocumab with placebo and oral ezetimibe in patients with hypercholesterolemia in a pha

151 here is a gradient in the restrictiveness of ezetimibe in public-funded formularies (most to least st

152 afety of the combination of simvastatin plus ezetimibe in such patients.

153 mice with NaHS, but not N-acetylcysteine or ezetimibe, inhibited the accelerated atherosclerosis dev

154 Moreover, ezetimibe inhibits infection by all major HCV genotypes

155 Ezetimibe inhibits intestinal cholesterol absorption and

156 Ezetimibe interacts with the intestinal cholesterol abso

157 C1L1 does not require endocytosis; moreover, ezetimibe interferes with NPC1L1's cholesterol adsorptio

158 Ezetimibe is a novel approach to reduce biliary choleste

159 We conclude that ezetimibe is both efficacious and tolerable in cardiac t

160 therapy with statins is well established and ezetimibe is often used as an additional LDL-C-lowering

161 of the healthcare system, if treatment with ezetimibe is targeted to high-risk patients.

162 how that co-administration of lovastatin and ezetimibe (L/E) significantly reverses hepatic triglycer

163 ce fed chow supplemented with lovastatin and ezetimibe (L/E) to decrease dietary sterol absorption an

164 Ezetimibe lowers plasma levels of low-density lipoprotei

165 t compared alirocumab with controls (placebo/ezetimibe), mainly as add-on therapy to maximally tolera

166 te intensive statin therapy, with or without ezetimibe, many patients are unable to achieve recommend

167 The cholesterol absorption inhibitor ezetimibe may offer a viable option for add on therapy;

168 These findings suggest that in humans, ezetimibe may reduce plasma cholesterol by inhibiting NP

169 The antiatherogenic effect of ezetimibe monitored by (99m)Tc-cAbVCAM1-5 SPECT showed a

170 One trial of ezetimibe monotherapy (n = 138) showed mean LDL-C decrea

171 ezetimibe therapy, switching from statins to ezetimibe monotherapy, having International Classificati

172 (-0.0124 +/- 0.0036 mm; p = 0.001), whereas ezetimibe (n = 161) did not reduce mean CIMT (-0.0016 +/

173 tatin (n=20) or 10 mg simvastatin plus 10 mg ezetimibe (n=19) for 6 weeks.

174 y 2 weeks (n=45) or every 4 weeks (n=45); or ezetimibe (n=45).

175 ulation of 1110 patients (fibrates, n = 220; ezetimibe, n = 890), 9.1% of fibrate users and 0.3% of e

176 As compared with ezetimibe, niacin had greater efficacy regarding the cha

177 orresponding to treatment differences versus ezetimibe of 37% to 39% (p <0.001).

178 However, the impact of ezetimibe on cardiovascular-related hospitalizations and

179 The effect of ezetimibe on carotid atherosclerosis is indeterminate, b

180 analysis showing superiority of niacin over ezetimibe on change in carotid intima-media thickness (C

181 timibe significantly enhanced the effects of ezetimibe on whole-body cholesterol metabolism and plasm

182 sed within 90 days of a new prescription for ezetimibe or a fibrate.

183 cacy was similar regardless of age or use of ezetimibe or apheresis, and was maintained for 12 weeks.

184 The treatment of ezetimibe or atorvastatin alone decreased effectively th

185 2-week washout, patients were randomized to ezetimibe or evolocumab for 24 weeks.

186 pathways and algorithms regarding the use of ezetimibe or PCSK9 inhibitors in primary prevention pati

187 Statin therapy compared with addition of ezetimibe or PCSK9 inhibitors.

188 Adding ezetimibe or PCSK9 monoclonal antibodies to maximally to

189 g, or 420 mg; AMG145 at 420 mg plus 10 mg of ezetimibe; or 10 mg of ezetimibe plus placebo.

190 vents (MACE) has been observed in statin and ezetimibe outcomes trials down to achieved levels of 54

191 The effect of formulary policy on the use of ezetimibe over time is unknown.

192 % more than placebo and 38% to 40% more than ezetimibe (p < 0.001 for all comparisons).

193 )H-tracer was 61% lower in mice treated with ezetimibe (P < 0.001).

194 ppear to derive benefit from the addition of ezetimibe (p interaction = 0.010).

195 nation of 80 mg of atorvastatin and 10 mg of ezetimibe (P<0.001 for all comparisons).

196 ibe placebo+phytosterol placebo, (2) 10 mg/d ezetimibe+phytosterol placebo, and (3) 10 mg/d ezetimibe

197 treatment with control, ezetimibe alone, and ezetimibe+phytosterols averaged 129 mg/dL (95% CI, 116 t

198 eived a phytosterol-controlled diet plus (1) ezetimibe placebo+phytosterol placebo, (2) 10 mg/d ezeti

199 420 mg plus 10 mg of ezetimibe; or 10 mg of ezetimibe plus placebo.

200 Lipid-lowering therapy with ezetimibe plus simvastatin improved clinical outcomes.

201 atins in individuals with CKD was shown with ezetimibe plus simvastatin versus placebo.

202 R in 18,015 individuals from the IMPROVE-IT (ezetimibe plus simvastatin versus simvastatin alone in i

203 lly available FDA-approved NPC1L1 antagonist ezetimibe potently blocks HCV uptake in vitro via a viri

204 Ezetimibe prevented gallstones by effectively reducing i

205 Treatment with ezetimibe promoted the dissolution of gallstones by form

206 on of intestinal cholesterol absorption with ezetimibe promotes antiatherosclerotic effects through i

207 ryl oleate-labeled human LDL to test whether ezetimibe promotes LDL-derived cholesterol fecal excreti

208 ced LDL cholesterol and triglyceride levels; ezetimibe reduced the HDL cholesterol and triglyceride l

209 n of Niemann-Pick C1 Like 1 transporter with ezetimibe reduced the hypercholesterolemic effect of [Th

210 zebrafish with a cholesterol-lowering agent, ezetimibe, reduced susceptibility to S Typhi.

211 Inhibition of NPC1L1 by its inhibitor ezetimibe reduces stool output in specific pathogen-free

212 40 alirocumab, n = 1,894 control [placebo or ezetimibe]; representing 4,029 [alirocumab] and 2,114 [c

213 effects, the use of evolocumab compared with ezetimibe resulted in a significantly greater reduction

214 of follow-up, allocation to simvastatin plus ezetimibe resulted in an average LDL cholesterol differe

215 When added to statin therapy, ezetimibe resulted in incremental lowering of LDL choles

216 PC1L1-GFP) endocytosis failed to inhibit the ezetimibe-sensitive uptake of [(3)H]cholesterol from tau

217 trated lipid-altering efficacy and safety of ezetimibe, several CAIs have been identified; all to dat

218 Mice treated with ezetimibe showed a 173% higher LDL-cholesteryl ester pla

219 Administering ezetimibe significantly diminished the HCD-induced endot

220 The addition of phytosterols to ezetimibe significantly enhanced the effects of ezetimib

221 Furthermore, ezetimibe significantly reduced biliary cholesterol satu

222 or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels i

223 L) at 1 month were more likely randomized to ezetimibe/simvastatin (85%), had lower baseline LDL-C va

224 ed the safety and lipid-altering efficacy of ezetimibe/simvastatin (E/S) coadministered with extended

225 rol 50 to 125 mg/dL were randomized to 40 mg ezetimibe/simvastatin (E/S) or 40 mg placebo/simvastatin

226 in cholesterol (LDL-C)-reducing therapy with ezetimibe/simvastatin compared with simvastatin alone wa

227 density lipoprotein cholesterol therapy with ezetimibe/simvastatin in IMPROVE-IT (IMProved Reduction

228 More patients treated with ezetimibe/simvastatin met dual targets than those treate

229 Significantly more patients treated with ezetimibe/simvastatin met prespecified and exploratory d

230 e analyzed in patients randomized to receive ezetimibe/simvastatin or placebo/simvastatin in IMPROVE-

231 cluding the first and all recurrent strokes, ezetimibe/simvastatin reduced stroke of any etiology (HR

232 were randomized to a placebo/simvastatin or ezetimibe/simvastatin regimen and followed for a median

233 the first event, would also be reduced with ezetimibe/simvastatin therapy.

234 ence interval [CI], 0.73-1.00; P=0.052) with ezetimibe/simvastatin versus placebo/simvastatin, driven

235 events were significantly reduced by 9% with ezetimibe/simvastatin vs placebo/simvastatin (incidence-

236 CRP targets and outcomes for simvastatin and ezetimibe/simvastatin was prespecified in Improved Reduc

237 eduction in CV death/MI/iCVA at 7 years with ezetimibe/simvastatin, thus translating to a number-need

238 er acute coronary syndrome to simvastatin or ezetimibe/simvastatin.

239 polymorphisms in the NPC1L1 gene (target of ezetimibe), the HMGCR gene (target of statins), or both

240 y applied for stereoselective preparation of Ezetimibe, the commercial cholesterol absorption inhibit

241 ponded modestly to maximum rosuvastatin plus ezetimibe therapy, even in combination with a PCSK9 mono

242 l prespecified subgroups had lower cost with ezetimibe therapy, patients with diabetes mellitus, pati

243 py, including moderate-intensity statin plus ezetimibe therapy, rates of nonadherence are reported in

244 ned as down-titrating statins and initiating ezetimibe therapy, switching from statins to ezetimibe m

245 : uptitration to atorvastatin, 80 mg; add-on ezetimibe therapy; add-on alirocumab therapy, 75 mg (a P

246 sms may contribute to the benefits of adding ezetimibe to a statin therapy.

247 ing the efficacy of evolocumab, placebo, and ezetimibe to improve lipid parameters in adult patients

248 Adding ezetimibe to reduce low-density LDL-C by 20% would provi

249 demonstrated no benefit with the addition of ezetimibe to simvastatin (Pint =0.034).

250 investigated the efficacy of the addition of ezetimibe to simvastatin for the prevention of stroke an

251 The addition of ezetimibe to simvastatin in patients stabilized after ac

252 derive greatest benefit from the addition of ezetimibe to statin therapy for secondary prevention aft

253 Addition of ezetimibe to statin therapy in patients with a recent ac

254 on of clinical benefits from the addition of ezetimibe to statin therapy in subjects with acute coron

255 t potential for benefit from the addition of ezetimibe to statin therapy.

256 ical outcomes with the addition of niacin or ezetimibe to statin treatment.

257 In IMPROVE-IT, the benefit of adding ezetimibe to statin was enhanced in patients with DM and

258 503,000 per QALY gained compared with adding ezetimibe to statins (80% uncertainty interval [UI], $49

259 ity C-reactive protein (hs-CRP); addition of ezetimibe to statins further reduces LDL-C and hs-CRP.

260 l (55% [47-63] vs placebo and 34% [26-41] vs ezetimibe), total cholesterol (38% [32-44] vs placebo an

261 g was stopped for muscle symptoms in 5 of 73 ezetimibe-treated patients (6.8%) and 1 of 145 evolocuma

262 Muscle symptoms were reported in 28.8% of ezetimibe-treated patients and 20.7% of evolocumab-treat

263 2% of evolocumab-treated patients and 23% of ezetimibe-treated patients.

264 examined before (day 0) and at 30 days after ezetimibe treatment (20 mg/day).

265 t findings suggest that NPC1L1 deficiency or ezetimibe treatment also prevents diet-induced hepatic s

266 the recommendation for statin or statin with ezetimibe treatment of adults aged 50 years or older wit

267 er or lower than 4.1 mmol/L) and by baseline ezetimibe use (yes/no).

268 Ezetimibe use has steadily increased in Canada during th

269 a from June 2003 to December 2012 to examine ezetimibe use in these 4 provinces to better understand

270 Ezetimibe use peaked at 12.1% and declined to 4.6% by th

271 Ezetimibe use remains common, increasing during the past

272 The gradient in ezetimibe use was related to variability in restrictiven

273 betes mellitus, a defective allele mutation, ezetimibe use, and the absence of previous ASCVD were pr

274 found regional variations in the patterns of ezetimibe use.

275 iacin, fibrates, bile acid sequestrants, and ezetimibe) use among Medicare beneficiaries with coronar

276 Compared with ezetimibe users (n = 61,831), fibrate users (n = 19,072)

277 n = 890), 9.1% of fibrate users and 0.3% of ezetimibe users had an increase in serum creatinine leve

278 RD (1057 [33.9%] cases with simvastatin plus ezetimibe versus 1084 [34.6%] cases with placebo; rate r

279 (Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclero

280 erefore, we aimed to examine the efficacy of ezetimibe versus placebo in reducing liver fat by the ma

281 tinal bleeding, and a study of simvastatin + ezetimibe versus simvastatin alone in 6-month cardiovasc

282 Trial) to examine the impact of simvastatin-ezetimibe versus simvastatin-placebo on cardiovascular-r

283 lerotic events (526 [11.3%] simvastatin plus ezetimibe vs 619 [13.4%] placebo; rate ratio [RR] 0.83,

284 LDL-C level at week 24 with ezetimibe was 181.5 mg/dL; mean percent change, -16.7% (

285 he mean of weeks 22 and 24, LDL-C level with ezetimibe was 183.0 mg/dL; mean percent LDL-C change, -1

286 Ezetimibe was not significantly better than placebo at r

287 n (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and pla

288 g/dL) despite statin therapy with or without ezetimibe were randomized 1:1:1 to AMG 145 350 mg, AMG 1

289 Subjects taking simvastatin and/or ezetimibe were randomized to receive extended-release (E

290 he LDL cholesterol level in association with ezetimibe were significantly associated with an increase

291 on a stable dose of statin (with or without ezetimibe), were randomly assigned equally, through an i

292 Ezetimibe, when added to simvastatin therapy, reduces ca

293 Ezetimibe, when added to simvastatin, reduces cardiovasc

294 We hypothesize that ezetimibe, which inhibits intestinal cholesterol absorpt

295 (for 3 weeks between birth and weaning) with ezetimibe, which is secreted into milk.

296 tine and liver and is the target of the drug ezetimibe, which is used to treat hypercholesterolemia.

297 In 1 trial (n = 248), ezetimibe with simvastatin resulted in greater LDL-C red

298 espite intensive statin use, with or without ezetimibe, with minimal adverse events and good tolerabi

299 Allocation to simvastatin plus ezetimibe yielded an average LDL cholesterol difference

300 In this study, we used ezetimibe (Zetia), a specific, FDA-approved, cholesterol